Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
With
National Cancer Institute (NCI)
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Cytologically or histologically confirmed metastatic breast cancer
Measurable or evaluable disease
Age \> 18, PS 0,1,2
MUGA \> 45%
Received one or fewer chemotherapies or investigational regimens for metastatic disease, no limit to the number of prior hormonal therapies. May have had single agent Herceptin and/or Herceptin plus single-agent chemotx.
Must meet designated laboratory criteria within 14 days of enrollment
You may not be if
Doxorubicin for metatstatic disease.
Pregnant or lactating.
Active infections, no myocardial infarction within 2 months of enrollment.
Investigational drugs within 14 days of enrollment.
Chemotherapy, radiotherapy, hormonal therapy or other investigational therapy within 4 weeks of enrollment.
Neuropathy that is \> grade 2.
Active brain mets.
Hypersensitivity to bortezomib, boron, or mannitol.
Clareo Health | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
